Brief: Yakult To Transfer Marketing Authorization Of Anticancer Drug Elplat To Takata Pharmaceutical
24/10/2023 10:33
Yakult Honsha Co Ltd 2267.T :
* YAKULT: TO TRANSFER MARKETING AUTHORIZATION OF ANTICANCER
DRUG
ELPLAT TO TAKATA PHARMACEUTICAL
Source text for Eikon: ID:
Further company coverage: 2267.T
Recent news on Yakult Honsha
See all newsBrief: Dalton Investments Sends Letter To Yakult Honsha
Table: Yakult -Q1 group results
To Cancel 5.53 Million Shares, 1.79% Of Outstanding Shares, On June 30
Japanese firms field record proposals from activists at this year's shareholder meetings
Brief: Murakami-Linked City Index Eleventh Takes 1.6% Stake In Yakult Honsha Co, AGM Notice Shows